LimongelliGMondaETramonteS, et al.Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int J Cardiol.. Epub ahead of print 4 July 2019. DOI: 10.1016/j.ijcard.2019.06.073.
2.
LiuQLiDBergerAE, et al.Survival and prognostic factors in hypertrophic cardiomyopathy: A meta-analysis. Sci Rep2017; 7: 11957.
3.
NorrishGCantaruttiNPissaridouE, et al.Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 1220–1230.
4.
GragnanoFGoliaENataleF, et al.Von Willebrand factor and cardiovascular disease: From a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol2017; 15: 404–415.
5.
GangulyPAlamSF. Role of homocysteine in the development of cardiovascular disease. Nutr J2015; 14: 6.
6.
SpenceJD. Homocysteine lowering for stroke prevention: Unravelling the complexity of the evidence. Int J Stroke2016; 11: 744–747.
